Sai Life Sciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹556Cr
- +26.4% YoY
- +3.5% QoQ
- Net profit
- ₹100Cr
- +85.2% YoY
- +19% QoQ
- Margin
- 34%
- +7 pp YoY
- +7 pp QoQ
Guidance rank: #68 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand. Sai Life Sciences has demonstrated strong growth with Q3 FY ‘26 revenue up 27% YoY and EBITDA margin expanding to around 34%.
From Sai Life Sciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand.
- The company foresees 15% to 20% revenue CAGR over a three-year period, with some years possibly outperforming this range.
- New capacity expansions, including a new mixed-use facility near Hyderabad (non-GMP, peptide, and GMP capacity), are planned to support growth.
- Current capacity utilization is around 60%, leaving headroom for near-term growth without immediate incremental capacity.
- Growth will be bolstered by both development and commercial contracts, with diversification across multiple molecules and modalities.
- Visibility from customer discussions indicates ongoing active engagements and pipeline progress feeding future capacity requirements.
2 more points from Sai Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sai Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Adding 450 KL manufacturing capacity in FY’27, increasing capacity by ~70%.
- Starting expansion of a new mixed-use site in Hyderabad, expected to be operational within 18-24 months; will include non-GMP, peptide, and GMP capacities.
- Animal health Phase I expansion targeted for completion by March ’27, enabling validation and commercialization of veterinary API products; current investment less than INR 50 crores with an additional INR 70-75 crores planned for next phase.
- Ongoing R&D expansions:
- First phase at Hyderabad Unit 8 commissioning in Q4 FY’26 with ~200 fume hoods.
- New process facility R&D building commissioning by Sept ’26, doubling process R&D capacity.
- Peptide process development and pilot facility targeted for Sept ’26.
- OEB laboratories for ADC capabilities completion by Oct ’26.
2 more points from Sai Life Sciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Sai Life Sciences Ltd's call on order book
Create a free account to keep reading this call
Sai Life Sciences Ltd — Quarterly revenue & net profit
Sai Life Sciences Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 556 | 440 | +26.4% | 537 | +3.5% |
| Operating profit (EBITDA) | 188 | 120 | +56.7% | 146 | +28.8% |
| Operating margin | 34% | 27% | +7 pp | 27% | +7 pp |
| Profit before tax | 134 | 72 | +86.1% | 112 | +19.6% |
| Net profit (PAT) | 100 | 54 | +85.2% | 84 | +19% |
| EPS (₹) | 4.75 | 2.59 | +83.4% | 4.00 | +18.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹659 Cr, net profit ₹98 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Life's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call analysis →
Earlier calls (2)
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sai Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sai Life Sciences Ltd Q3 FY26 results?
Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand. Sai Life Sciences has demonstrated strong growth with Q3 FY ‘26 revenue up 27% YoY and EBITDA margin expanding to around 34%.
What is Sai Life Sciences Ltd share price analysis?
Sai Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 83.4 with a market cap of ₹29,600 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Life Sciences Ltd planning capital expenditure?
Adding 450 KL manufacturing capacity in FY’27, increasing capacity by ~70%.
Keep Sai Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
